Exploiting gut bacteriophages for human health

Trends in Microbiology

Volumn 22, Issue 7, 2014, Pages 399-405

  Dalmasso, Marion ^a,b   Hill, Colin ^a,b   Ross, R Paul ^b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c TEAGASC FOOD RESEARCH CENTRE   (Ireland)

Author keywords

Bacteriophage; Human health; Phage therapy; Phageome

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIAL CLEARANCE; BACTERIAL IMMUNITY; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIOPHAGE; CLOSTRIDIUM ACETOBUTYLICUM; CLOSTRIDIUM DIFFICILE; CROHN DISEASE; DISEASE MARKER; DISEASE PREDISPOSITION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FOOD COMPOSITION; FOOD CONTAMINATION; FOOD SAFETY; HUMAN; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; BIOLOGICAL THERAPY; FOOD CONTROL; FOOD INDUSTRY; GASTROINTESTINAL TRACT; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; VIROLOGY;

BACTERIA (MICROORGANISMS);

VIRUS VACCINE;

BACTERIOPHAGES; BIOLOGICAL THERAPY; FOOD INDUSTRY; FOOD MICROBIOLOGY; GASTROINTESTINAL TRACT; HUMANS; VIRAL VACCINES;

EID: 84903616167     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.02.010     Document Type: Review

References (69)

1. Weinbauer M.G. Ecology of prokaryotic viruses. FEMS Microbiol. Rev. 2004, 28:127-181.
2. Los M., Wegrzyn G. Pseudolysogeny. Adv. Virus Res. 2012, 82:339-349.
3. Wittebole X., et al. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2014, 4:1-10.
4. Endersen L., et al. Phage therapy in the food industry. Annu. Rev. Food Sci. Technol. 2014, 5:327-349.
5. Henry M., Debarbieux L. Tools from viruses: bacteriophage successes and beyond. Virology 2012, 434:151-161.
6. Lepage P., et al. A metagenomic insight into our gut's microbiome. Gut 2013, 62:146-158.
7. Mills S., et al. Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes 2013, 4:4-16.
8. Breitbart M., et al. Metagenomic analyses of an uncultured viral community from human feces. J. Bacteriol. 2003, 185:6220-6223.
9. Barr J.J., et al. Innate and acquired bacteriophage-mediated immunity. Bacteriophage 2013, 3:e25857.
10. Duerkop B.A., Hooper L.V. Resident viruses and their interactions with the immune system. Nat. Immunol. 2013, 14:654-659.
11. Gorski A., et al. Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 2006, 46:313-319.
12. Sharma M. Lytic bacteriophages: potential interventions against enteric bacterial pathogens on produce. Bacteriophage 2013, 3:e25518.
13. Brovko L.Y., et al. Bacteriophages for detection and control of bacterial pathogens in food and food-processing environment. Adv. Food Nutr. Res. 2012, 67:241-288.
14. Mahony J., et al. Bacteriophages as biocontrol agents of food pathogens. Curr. Opin. Biotechnol. 2011, 22:157-163.
15. Johnson R.P., et al. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. Anim. Health Res. Rev. 2008, 9:201-215.
16. Woolston J., et al. Bacteriophages lytic for Salmonella rapidly reduce Salmonella contamination on glass and stainless steel surfaces. Bacteriophage 2013, 3:e25697.
17. Chibeu A., et al. Efficacy of bacteriophage LISTEXP100 combined with chemical antimicrobials in reducing Listeria monocytogenes in cooked turkey and roast beef. Int. J. Food Microbiol. 2013, 167:208-214.
18. Carlton R.M., et al. Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul. Toxicol. Pharmacol. 2005, 43:301-312.
19. Minot S., et al. The human gut virome: inter-individual variation and dynamic response to diet. Genome Res. 2011, 21:1616-1625.
20. Alemayehu D., et al. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012, 3. e00029-12.
21. Chhibber S., et al. Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS ONE 2013, 8:e56022.
22. Krylov V., et al. A genetic approach to the development of new therapeutic phages to fight Pseudomonas aeruginosa in wound infections. Viruses 2012, 5:15-53.
23. Mendes J.J., et al. Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. Wound Repair Regen. 2013, 21:595-603.
24. Maura D., et al. Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine. Antimicrob. Agents Chemother. 2012, 56:6235-6242.
25. Tothova L., et al. Phage survival: the biodegradability of M13 phage display library in vitro. Biotechnol. Appl. Biochem. 2012, 59:490-494.
26. Barbosa C., et al. Co-evolutionary dynamics of the bacteria Vibrio sp. CV1 and phages V1G, V1P1, and V1P2: implications for phage therapy. Microb. Ecol. 2013, 66:897-905.
27. Betts A., et al. Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1. Evol. Appl. 2013, 6:1054-1063.
28. Meader E., et al. Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 2013, 22:25-30.
29. Rea M.C., et al. Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection. J. Med. Microbiol. 2013, 62:1369-1378.
30. Chan B.K., et al. Phage cocktails and the future of phage therapy. Future Microbiol. 2013, 8:769-783.
31. Huys I., et al. Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy. EMBO Rep. 2013, 14:951-954.
32. Miedzybrodzki R., et al. Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res. 2008, 131:233-242.
33. Przerwa A., et al. Effects of bacteriophages on free radical production and phagocytic functions. Med. Microbiol. Immunol. 2006, 195:143-150.
34. Ksendzovsky A., et al. Convection-enhanced delivery of M13 bacteriophage to the brain. J. Neurosurg. 2012, 117:197-203.
35. Dabrowska K., et al. Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res. 2004, 24:3991-3995.
36. Eriksson F., et al. Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunol. Immunother. 2007, 56:677-687.
37. Pajtasz-Piasecka E., et al. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma. Immunol. Lett. 2008, 116:24-32.
38. Shoae-Hassani A., et al. λ Phage nanobioparticle expressing apoptin efficiently suppress human breast carcinoma tumor growth in vivo. PLoS ONE 2013, 8:e79907.
39. Kia A., et al. Inhibition of histone deacetylation and DNA methylation improves gene expression mediated by the adeno-associated virus/phage in cancer cells. Viruses 2013, 5:2561-2572.
40. Thurber R.V., et al. Laboratory procedures to generate viral metagenomes. Nat. Protoc. 2009, 4:470-483.
41. Wagner J., et al. Bacteriophages in gut samples from pediatric Crohn's disease patients: metagenomic analysis using 454 pyrosequencing. Inflamm. Bowel Dis. 2013, 19:1598-1608.
42. Reyes A., et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 2010, 466:334-338.
43. Stern A., et al. CRISPR targeting reveals a reservoir of common phages associated with the human gut microbiome. Genome Res. 2012, 22:1985-1994.
44. Ogilvie L.A., et al. Genome signature-based dissection of human gut metagenomes to extract subliminal viral sequences. Nat. Commun. 2013, 4:2420.
45. Reyes A., et al. Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:20236-20241.
46. Modi S.R., et al. Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature 2013, 499:219-222.
47. Duerkop B.A., et al. A composite bacteriophage alters colonization by an intestinal commensal bacterium. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:17621-17626.
48. Maura D., Debarbieux L. On the interactions between virulent bacteriophages and bacteria in the gut. Bacteriophage 2012, 2:229-233.
49. Gasiunas G., et al. Molecular mechanisms of CRISPR-mediated microbial immunity. Cell. Mol. Life Sci. 2014, 71:449-465.
50. Seed K.D., et al. A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity. Nature 2013, 494:489-491.
51. Villion M., Moineau S. Virology: phages hijack a host's defence. Nature 2013, 494:433-434.
52. Barr J.J., et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:10771-10776.
53. Schwiertz A., et al. Development of the intestinal bacterial composition in hospitalized preterm infants in comparison with breast-fed, full-term infants. Pediatr. Res. 2003, 54:393-399.
54. Breitbart M., et al. Viral diversity and dynamics in an infant gut. Res. Microbiol. 2008, 159:367-373.
55. Mokili J.L., et al. Metagenomics and future perspectives in virus discovery. Curr. Opin. Virol. 2012, 2:63-77.
56. Reyes A., et al. Going viral: next-generation sequencing applied to phage populations in the human gut. Nat. Rev. Microbiol. 2012, 10:607-617.
57. Zhang T., et al. RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol. 2005, 4:e3.
58. Minot S., et al. Rapid evolution of the human gut virome. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:12450-12455.
59. Pride D.T., et al. Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome. ISME J. 2012, 6:915-926.
60. LaTuga M.S., et al. Beyond bacteria: a study of the enteric microbial consortium in extremely low birth weight infants. PLoS ONE 2011, 6:e27858.
61. Morowitz M.J., et al. Strain-resolved community genomic analysis of gut microbial colonization in a premature infant. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:1128-1133.
62. Sharon I., et al. Time series community genomics analysis reveals rapid shifts in bacterial species, strains, and phage during infant gut colonization. Genome Res. 2013, 23:111-120.
63. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
64. Hedin C.R., et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 2014, 0:1-9.
65. Lepage P., et al. Dysbiosis in inflammatory bowel disease: a role for bacteriophages?. Gut 2008, 57:424-425.
66. Andoh A., et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J. Gastroenterol. 2011, 46:479-486.
67. Perez-Brocal V., et al. Study of the viral and microbial communities associated with Crohn's disease: a metagenomic approach. Clin. Transl. Gastroenterol. 2013, 4:e36.
68. Segata N., et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011, 12:R60.
69. Henein A. What are the limitations on the wider therapeutic use of phage?. Bacteriophage 2013, 3:e24872.